MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparibMargaret Whicker(Yale University), Elena Ratner(Yale University)BMC CancerJuly 27, 201610.1186/s12885-016-2598-1Cited by 34SaveCiteExport RISWatch citationsRelated PapersTransforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib|Cancers|2023|6Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to Olaparib|Preprints.org|2023|5